Emerging research highlights the potential of ketogenic metabolic therapy, a specialized high-fat, low-carbohydrate diet, for treating certain mental illnesses. A new study from the University of Maryland School of Medicine's Maryland Psychiatric Research Center (MPRC) demonstrates that an immersive training program can enhance healthcare providers' confidence in implementing ketogenic dietary treatment plans. The research findings were published in the journal Frontiers in Psychiatry.
Read More
Ketogenic metabolic therapy comprises approximately 75% dietary fats, 20% protein, and less than 10% carbohydrates. This diet shifts the body’s metabolism from glucose reliance to using ketones, which may alleviate neurological and psychiatric symptoms resistant to traditional medications. The ketogenic diet is currently the standard treatment for children with epilepsy who do not respond to conventional seizure drugs, according to the Epilepsy Foundation. Recent studies suggest its potential role in managing psychiatric conditions, including schizophrenia, bipolar disorder, and depression.
Deanna L. Kelly, PharmD, BCPP, lead investigator and director of the Maryland Psychiatric Research Center, emphasized the need for healthcare professionals to be equipped with knowledge about this rapidly advancing field. She noted that understanding both the benefits and challenges of ketogenic therapy is crucial as new evidence emerges.
The study assessed a training program called "Live It ~ Launch It," developed by the University of Maryland team and supported by the Baszucki Group. The pilot study involved 40 healthcare professionals, including psychiatrists and psychologists, who completed a four-hour online course on the fundamentals of ketogenic therapy, its dietary variations, nutrition, and monitoring. A subset of 25 participants then experienced the ketogenic diet for four weeks with support from registered dietitians and nutrition specialists.
Results indicated that the combination of guided education and practical experience led to significantly increased clinician confidence in discussing the benefits and risks of ketogenic therapy with patients experiencing difficult-to-treat mental health disorders. This immersion helped clinicians better understand adherence challenges and foster patient engagement in decision-making about the treatment.
Kelly pointed out that many individuals with schizophrenia also face weight gain and metabolic issues exacerbated by antipsychotic medications, posing additional cardiovascular risks. A therapeutic approach that improves metabolic health while addressing psychiatric symptoms could represent significant progress.
The researchers caution that the findings are preliminary, and further studies are needed to assess whether training impacts clinical practice. They noted a pressing need for additional randomized controlled trials and long-term studies to determine the efficacy and proper clinical application of ketogenic diets in mental health care.
Sidney Murray, Ph.D., lead author, remarked on the value of firsthand experience in enhancing clinician understanding of the challenges patients may encounter. The research team is also preparing to release a companion paper detailing health outcomes of healthcare professionals during the ketogenic diet phase. These findings are intended to guide the development of future training and studies aimed at effectively integrating ketogenic metabolic therapy into mental health care.